HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation

Qiangqiang Zhong ^1,2, Baokang Zhao ^1,3, Xiao She ⁴

⁰Department of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.

Plos One +

|

November 26, 2024

View abstract on PubMed

Summary

High Mobility Group (HMG) proteins like HMGA2 are elevated in hepatocellular carcinoma (HCC), correlating with poorer patient survival. Targeting these HMG proteins may offer new therapeutic strategies for liver cancer.

Area Of Science

Oncology
Molecular Biology
Biochemistry

Background

Hepatocellular carcinoma (HCC) pathogenesis involves complex molecular mechanisms.
Understanding novel biomarkers and therapeutic targets is crucial for improving HCC patient outcomes.

Purpose Of The Study

To investigate the expression and clinical significance of High Mobility Group (HMG) proteins in HCC.
To identify HMG proteins as potential prognostic biomarkers and therapeutic targets for HCC.

Main Methods

Bioinformatic analysis of The Cancer Genome Atlas (TCGA) and other databases.
Quantitative reverse transcription PCR (qRT-PCR) for validating HMG expression in HCC cell lines.
Functional studies involving the knockdown of HMGA2 in HCC cell lines.

Main Results

Significant upregulation of HMG family members (HMGA1, HMGA2, HMGB2, HMGN1) observed in HCC tissues compared to normal tissues.
High HMG protein expression correlated with reduced overall and disease-specific survival in HCC patients.
HMGA2 knockdown suppressed HCC cell proliferation, migration, and invasion.

Conclusions

HMG proteins, particularly HMGA2, are promising prognostic biomarkers for HCC.
HMG proteins represent potential therapeutic targets for HCC treatment.
This study elucidates the role of HMG proteins in HCC progression, offering new insights.